Get started
Author

David Spaner

Observed names: D E Spaner, D Spaner, D. E. Spaner, D. Spaner, DAVID E. SPANER, David E Spaner, David E. Spaner, Spaner, D., Spaner, David
Observed institutions: Ontario Institute for Cancer Research, Roswell Park Comprehensive Cancer Center, National Institutes of Health, Sunnybrook Health Science Centre, University Health Network, Mayo Clinic, MRC Elsie Widdowson Laboratory, University of Toronto, Hospital for Sick Children, Princess Margaret Cancer Centre, Princess Margaret Hospital, Mayo Clinic in Arizona, Princess Margaret Hospital, National Cancer Institute, Institute for Clinical Evaluative Sciences, Princess Margaret Hospital, Sunnybrook Hospital, Celgene (United States), Sunnybrook Research Institute, Odette Cancer Centre, Medical Research Council, Saarland University
ORCID: 0000-0002-0783-7554
Observed ORCID: 0000-0002-0783-7554
OpenAlex ID: A5091653815
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
2014 · James N. Kochenderfer, Mark E. Dudley, et al. · Journal of Clinical Oncology · 1,594
PDF
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
2011 · James N. Kochenderfer, Mark E. Dudley, et al. · Blood · 1,441
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
2006 · Asher Chanan-Khan, Kena C. Miller, et al. · Journal of Clinical Oncology · 414
Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype
2009 · Raphaëlle Romieu-Mourez, Moïra François, et al. · The Journal of Immunology · 299
Hypersensitivity to natural latex
1989 · D. Spaner, J. Dolovich, et al. · Journal of Allergy and Clinical Immunology · 151
PDF
Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia
2010 · Y Shi, J Tomic, et al. · Leukemia · 140
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
2010 · Christine I. Chen, P. Leif Bergsagel, et al. · Journal of Clinical Oncology · 139
PDF
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
2016 · Sina Oppermann, Jarkko Ylanko, et al. · Blood · 122
PDF
Cytotoxic T Lymphocyte Reactivity to gp100, MelanA/MART-1, and Tyrosinase, in HLA-A2-Positive Vitiligo Patients
2003 · Rochelle L. Mandelcorn-Monson, Neil H. Shear, et al. · Journal of Investigative Dermatology · 112
PDF
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia
2006 · D E Spaner, A Masellis · Leukemia · 99
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
2004 · J. Mangel, H.A. Leitch, et al. · Annals of Oncology · 99
PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia
2013 · Stephanie Tung, Yonghong Shi, et al. · Blood · 98
PDF
The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice
2012 · Yanmei Li, Laura M. Vecchiarelli-Federico, et al. · Blood · 98
Comprehensive Lipidomics Analysis of Bioactive Lipids in Complex Regulatory Networks
2010 · Mojgan Masoodi, Michael Eiden, et al. · Analytical Chemistry · 91
Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells
2005 · D E Spaner, Y Shi, et al. · Leukemia · 84
PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia
2012 · D E Spaner, E Lee, et al. · Leukemia · 83
PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions
2016 · X Wang, G Wang, et al. · Oncogenesis · 80
PDF
Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma
2008 · L K Hicks, A Woods, et al. · Bone Marrow Transplantation · 71
A Role for Perforin in Activation-Induced T Cell Death In Vivo: Increased Expansion of Allogeneic Perforin-Deficient T Cells in SCID mice
1999 · David Spaner, Kaliannan Raju, et al. · The Journal of Immunology · 70
Soluble CD200 Is Critical to Engraft Chronic Lymphocytic Leukemia Cells in Immunocompromised Mice
2012 · Karrie K. Wong, Fred Brenneman, et al. · Cancer Research · 69
Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
1999 · R Buckstein, K Imrie, et al. · PubMed · 69
The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis
2010 · Gurpreet K. Lakhanpal, Laura M. Vecchiarelli-Federico, et al. · Blood · 60
A Role for Perforin in Activation-Induced Cell Death
1998 · David Spaner, Kaliannan Raju, et al. · The Journal of Immunology · 58
PDF
The role of CD200 in immunity to B cell lymphoma
2010 · Karrie K Wong, Ismat Khatri, et al. · Journal of Leukocyte Biology · 57
Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia
2011 · Jelena Tomic, Brian Lichty, et al. · Blood · 56
Works count: 181
Citation count: 7,711
H-index: 41
I10-index: 90
Year
Topic
Type